Merck Interest Areas

C O M B I N I N G S H A R I N G
O U R O U R
S T R E N G T H S S U C C E S S E S
Areas of Interest
December 2010
Merck is known as MSD outside the United States and Canada.
Dear Colleagues, I am delighted to invite you to discover more about Todays Merck and our partnership interests. Whether you are working for a biotechnology company, an academic institution, or a financial organization, we welcome the opportunity to discuss our shared interests and opportunities to partner. We are actively seeking new alliances that accelerate the discovery and development process, improve R&D productivity, and increase the probability of successfully commercializing novel therapeutics and vaccines. We understand that you are using your unique strengths to identify innovative new compounds and technologies. With Merck as your partner, you will find an organization devoted to you and the rigorous, expeditious development of your discovery. Inside this book you will find a list of our currently defined therapeutic areas of interest, including research technologies and biologics. We welcome:
Novel patented chemical or biological entities and vaccines in discovery and development Targets with proof of concept Molecules with a defined mechanism of action or testable hypothesis Technologies with patent protection that provide a competitive advantage
We are interested in compounds that have a large market potential for unmet medical needs. Late-stage clinical compounds with proven therapeutic value (Phase III-ready or later) are of particular interest in any therapeutic area. To begin a discussion about partnering with Merck, contact our scientific licensing expert in your region. Contact information for our licensing experts can be found in the back of this book. Or, if you prefer, please visit our Web site at merck.com/licensing. Im confident that, together, we can combine our strengths and translate cutting-edge science into breakthrough medicines. Sincerely,
David Nicholson, PhD

Senior Vice President and Head Worldwide Licensing and Knowledge Management
D E C E M B E R
2 0 1 0
C O M B I N I N G S H A R I N G
O U R O U R
S T R E N G T H S S U C C E S S E S
Deal MakingA Creative and Flexible Process

Our four-step partnership is clear and straightforward. From initial discussions to signing the deal, through to execution and global commercialization, youll experience flexibility, creativity, and the utmost professionalism.
Step 1 Connecting With You
Step 2 Understanding Your Science
Step 3 Doing the Deal
Step 4 Working Together
D E C EM B E R
2 0 1 0
AREAS
Of
I N T E R E S T
Therapeutic Areas and Research Technologies

Table of Contents
Atherosclerosis and Cardiovascular Diseases
Lipids / Metabolic Syndrome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .4 Specialty Hypertension / Cardiovascular. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .5 Thrombosis and Other Areas . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .6
Diabetes and Obesity

Diabetes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7 Obesity. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .7
Infectious Diseases
Antibacterials. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .9 Antifungals . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Antivirals HIV . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Antivirals Hepatitis C . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Antivirals Other Interests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Antiviral and Anti-infective Technologies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
Neurosciences and Ophthalmology

Migraine and Pain: Migraine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Migraine and Pain: Pain . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Neurology Alzheimers Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Neurology Parkinsons Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Ophthalmology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Psychiatric Diseases. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Sleep Disorders . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 14 15 16 16 17 17
Oncology
Oncology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18 Capabilities Technologies to Evaluate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Respiratory and Immunology

Arthritis and Immune-Based Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 Asthma / COPD / Rhinitis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
Womens Health and Endocrinology

Contraception . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Fertility . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Menopause. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Endometriosis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Bone . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Urology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Sarcopenia . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Other Diseases. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2
21 22 22 23 23 24 24 24
D E C E M B E R
2 0 1 0
A R EA S
O f
I NTER ES T
Biologics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25 Vaccines . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26 Research Technologies

RNA Therapeutics. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27 Drug Delivery and Formulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
Enabling Technologies
Translational Models / In Vivo Pharmacology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Lead Identification and Screening Assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Chemical Synthesis and Purification . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Modeling Tools . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Automated Workflows . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Information Technology / Software. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Analytical Technology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29 29 30 30 31 31 32 32
We have aligned our areas of interest with our

franchises, plus new technologies and biologics.
Additionally, we will continue to pursue

external licensing opportunities in other disease areas where clinical proof of concept exists.
We will also pursue niche acquisitions and

partnerships in diagnostics and devices where it complements our pipeline, and not as a stand-alone business.
D E C EM B E R
2 0 1 0
ATHEROSC lEROSIS
AND
CARDIO vASCU lAR
D I S E A S E S
Atherosclerosis and Cardiovascular Diseases

LIpIds / MetAboLIc syndroMe
Areas of Interest: Not Interested in:
Lipid-lowering therapies Agents with effect on LDL / Apo-B Agents with additional effect on glucose, triglycerides, blood pressure, body weight, and / or HDL Basic research collaborations on novel targets HDL-raising therapies Acute HDL therapy for high-risk patients (eg, HDL infusion) Oral compounds, with known mechanism of action, that increase HDL-C or Apo-A1 levels and have additional evidence to increase confidence that such mechanism will reduce cardiovascular risk Basic research collaborations on novel targets
Triglyceride-lowering therapies with no other benefit Fibrates or other PPAR-alpha agonists Nutraceuticals
Technology / Methods:
Discovery Collaborations for identifying, validating, and developing novel lipid / metabolic and / or other emerging targets with high confidence for reducing CV risk Biomarkers Methods, biomarkers, or platforms to assess antiatherogenic properties of HDL or other lipoproteins Biomarkers of patient subtypes Acute methods to assess cholesterol transport in humans (especially reverse cholesterol transport), including imaging and kinetic models
D E C E M B E R
2 0 1 0
AT H E R O S ClE R O S IS
A N D
C A R D I OvA S C UlA R
DI S EA S ES
specIALty HypertensIon* / cArdIovAscuLAr

Diuretics Long-acting vasorelaxants Agents that inhibit aldosterone synthesis and / or action Agents that lower blood pressure and have pleiotropic benefits on end-organ protection (especially cardiac, renal, and vascular) Antihypertensive agents with additional benefits on other components of metabolic syndrome and other cardiovascular risk factors Agents for pulmonary artery hypertension Heart failure agents that affect structural cardiac remodeling and / or have antihypertensive effects Basic research
ACE inhibitors, ARBs, CCBs, beta-blockers, adrenergic agents Nutraceuticals
Discovery Platform technologies for identifying novel targets for specialty hypertension Animal models of hypertension Biomarkers (clinical and preclinical) Technologies for measuring vascular dynamics (eg, flow, shear stress, vascular compliance) and intravascular pressure beyond tonometry Markers that link HTN to other metabolic syndrome phenotypes and / or atherosclerosis Markers for renal sequelae of HTN (eg, renal perfusion and renal injury) Platform technologies that enable personalized medicine for HTN
*Specialty hypertension includes hypertensive segments with high unmet need such as systolic HTN, resistant HTN and HTN associated with obesity and diabetes HTN with associated heart failure, and pulmonary artery HTN
Late-Stage Opportunities:
We will continue to pursue external licensing and partnership opportunities for differentiated products in all disease areas in late-stage development (Phase III-ready and later).
5
D E C EM B E R
2 0 1 0
ATHEROSC lEROSIS
AND
CARDIO vASCU lAR
D I S E A S E S
tHroMbosIs And otHer AreAs (outsIde LIpIds And HypertensIon)

Areas of Interest:
Thrombosis (discovery onward): Anticoagulation agents with improved therapeutic index relative to existing agents Basic research collaborations on novel targets Biomarkers that can be used to quantify antithrombotic effects, antiplatelet effects, and bleeding risk
Not Interested in:
Agents without clinical POC for: Acute treatments for myocardial infarction (MI) Post- myocardial infarction therapeutics for myocardial preservation or perfusion-reperfusion injury Vascular inflammation targets Treatment of restenosis
The following areas of interest apply to compounds that have established proof of concept (POC) in clinical Phase II studies:
Antiarrhythmic agents for atrial fibrillation
D E C E M B E R
2 0 1 0
DI A B ETES
A ND
OB ES I Ty
Diabetes and Obesity

dIAbetes
Areas of Interest:
obesIty
Areas of Interest:
Any treatments for glucose with risk reduction of comorbidities (eg, dyslipidemia, hypertension) Novel or best-in-class protein / peptide therapeutics; consider strategic alliance Insulin Novel breakthrough insulins (eg, glucose dependent, liver targeted) Insulin delivered by alternate routes that also offers an improved clinical profile (eg, oral, buccal, transdermal, nasal) Once-weekly basal insulin (sc) Best-in-class GLP-1 analogues Oral therapies: Best-in-class and novel mechanisms Non-PPAR insulin sensitizers Glucose-dependent insulin secretagogues (GDIS) Beta-cell protection or regeneration if it also affects GDIS Ability to combine with metformin is a must-have Additive / synergistic in combination with sitagliptin Best-in-class SGLT inhibitor Microvascular complication treatments with human clinical efficacy data Agents that halt / reverse complications in preferably >1 target (diabetic nephropathy, neuropathy, retinopathy)
Best-in-class compounds and novel mechanisms for weight loss or both weight loss and prevention of weight gain Novel mechanisms for weight loss or both weight loss and prevention of weight gain Any effective mechanism, eg, those acting centrally or peripherally on appetite, satiety, or metabolic rate, and nutrient absorption inhibitors Peptide, protein, or oral small molecule Independent effects on comorbidities (blood pressure, glucose, lipids) desirable Early-stage opportunities: with robust animal mechanismbased POC and preclinical safety data desirable Clinical stage compounds: meet registration criteria for obesity indication with better safety and tolerability vs current agents Mechanisms that are additive or synergistic as combination therapy
7
D E C EM B E R
2 0 1 0
D IABETES
AN D
O B E S I Ty
dIAbetes And obesIty

Technologies / Capabilities: Not Interested in:
Alternate delivery of peptides Novel delivery devices for sc insulin Platform technologies for the identification and validation of novel targets to complement existing efforts Imaging agents for monitoring pancreatic beta-cell mass Pharmacogenetics / -genomics, proteomics, or other for prediction of diabetes, obesity, drug response, and subphenotyping of disease. Clinical validation data are needed Clinical methods for early prediction of long-term weight loss
Nutraceuticals or natural product mixtures Nonglucose-dependent insulin secretagogues Cell-based insulin replacement for type 1 diabetes unless long-term clinical POC data exists Compounds with unknown molecular target unless clinical POC exists
D E C E M B E R
2 0 1 0
I NfEC TI O U S
D I S EA S ES
Infectious Diseases
AntIbActerIALs
Antibacterial agents with compelling data including: resistance frequency, an understanding of the mechanism of action, efficacy in animal models of infection, and preliminary toxicology data Narrow and broad-spectrum agents that cover problematic pathogens with either intrinsic or acquired resistance to existing agents, particularly MRSA (IV and oral formulations), Pseudomonas (IV, preferably with oral formulation), and Acinetobacter (IV, preferably with oral formulation) Novel approaches to C. difficile that address the recurrence rate Combinations that address bacterial resistance such as: Beta lactamase (Class A / C / D) inhibitors Carbapenem potentiators or synergists
Topical antibiotics Antibodies without clinical POC Quinolones (mechanism of action for quinolones is of interest, but not the structural class) Known antibacterial structural types unless they are differentiated from current agents by safety, efficacy, route of administration, or activity on resistant strains
Late-stage opportunities (Phase III-ready and later):

Gram-positive and / or gram-negative products that can be meaningfully clinically differentiated* from current treatment options. Also includes: Gram-positive (w / MRSA): At least with oral formulation Community RTI oral agents
*Criteria that determine meaningful clinical differentiation may vary by region of the world
9
D E C EM B E R
2 0 1 0
IN fECTIOUS
D I S E A S E S
AntIfungALs
Antifungal agents with compelling data including: an understanding of the mechanism of action, efficacy in animal models of infection, and preliminary toxicology data IV (preferably with oral formulation) broad-spectrum agents with activity over azoles and echinocandins against Candida, Aspergillus, and rare moulds for hospital use Aspergillus- or mould-specific small molecule or mAb (therapeutic and / or prophylactic, clinical POC required)
Incremental improvements upon inhibitors of ergosterol biosynthesis Known antifungal structural types unless they are differentiated from current agents by safety, efficacy, route of administration, or activity on resistant strains Antibodies without clinical POC
Late-stage opportunities (Phase III-ready and later):
Candida, Aspergillus, or rare mould antifungals (IV, preferably with oral formulation) that can be meaningfully clinically differentiated from current treatment options* Oral agents for community use active against Candida and dermatophytes that can be meaningfully clinically differentiated from current treatment options*
*Criteria that determine meaningful clinical differentiation may vary by region of the world
10
D E C E M B E R
2 0 1 0
I NfEC TI O U S
D I S EA S ES
AntIvIrALs HIv
Areas of Interest:
Preclinical: Novel agents with compelling data including an understanding of the mechanism of action, activity in cell culture, resistance profile, and PK with particular interest in: RNase H inhibitors Inhibitors of viral budding and / or maturation Latency targets HIV gene expression inhibitors Active-site non-nucleoside inhibitors Nucleoside reverse transcriptase inhibitors with differentiated resistance profile to existing agents, QD dosing, >1 month tox. Other new mechanisms, eg, host targets PK enhancers Phase I or later in development: Integrase inhibitors with new MOA or novel structural scaffold with QD dosing; BID dosing considered with a differentiated resistance profile Protease inhibitors that do not require ritonavir-boosted QD dosing; BID dosing considered with a differentiated resistance profile Non-nucleoside reverse transcriptase inhibitors dosed QD with a high barrier to resistance / efficacy against NNRTI (including 2nd-generation NNRTI)-resistant virus Late-stage opportunities (Phase III-ready and later): Novel or differentiated agents, ideally combinable in fixeddose combination with existing in-line or pipeline assets that are complementary to in-house MOAs Global / regional promotional partnerships
Not Interested in:
Agents administered parenterally, including antibodies
11
D E C EM B E R
2 0 1 0
IN fECTIOUS
D I S E A S E S
AntIvIrALs HepAtItIs c
Areas of Interest:
Preclinical: Novel agents with compelling data including an understanding of the mechanism of action, activity in HCV replicon, and PK in one species with particular interest in: Nucleoside inhibitors Small-molecule inhibitors of HCV helicase NS5A inhibitors Novel mechanism agents PK enhancers Phase I or later in development: Non-nucleoside inhibitors of NS5B Second-generation protease inhibitor with activity against genotypes 1, 2, and 3, and key mutants with preclinical safety data and PK suggestive of QD dosing suitable for development as fixed-dose combinations Cyclophillin inhibitors Late-stage opportunities (Phase III-ready and later): Novel or differentiated agents, ideally suitable for fixeddose combination with existing in-line or pipeline assets that are complementary to in-house MOAs Global / regional promotional partnerships
Not Interested in:
Parenterally administered interferons TLR agonists or activators HCV viral entry inhibitors
AntIvIrALs otHer Interests

Areas of Interest:
Preclinical or later in development: Novel approaches to HBV Phase IIb or later in development: HBV, RSV, CMV, EBV, flu agents with pristine safety profiles Late-stage opportunities (Phase III-ready and later): We will continue to consider external licensing and partnership opportunities for differentiated products directed at other viral infections in late-stage development Global / regional promotional partnerships
Not Interested in:
Agents administered parenterally
12
D E C E M B E R
2 0 1 0
I NfEC TI O U S
D I S EA S ES
AntIvIrAL And AntI-InfectIve tecHnoLogIes

Areas of Interest:
Animal or cellular models of latency In vitro tissue models for HCV Robust cell culture systems for HCV replication Biomarkers / noninvasive assay technology for HIV and HCV with enhanced sensitivity and / or lower cost; particularly interested in prognostics Genotyping and phenotyping technologies for HCV polymerase and HCV protease HCV and specific gene chimera replicons PK enhancers
Antifungal and Antibacterial:
Rapid (<2 hours), point-of-care, pathogen-specific (ESKAPE organisms), and host-response diagnostic tests Molecular biomarkers of susceptibility
13
D E C EM B E R
2 0 1 0
N EUROSCIENCES
AND
OpHTH A l M Ol O G y
Neurosciences and Ophthalmology

MIgrAIne And pAIn: MIgrAIne
Areas of Interest*: Not Interested in:
Novel therapeutic agents that, alone or in combination, address unmet needs in migraine or migraine prophylaxis Biologics for prophylaxis Mechanisms that complement CGRP antagonists for acute migraine Synergistic combination approaches
Triptans COX-2 inhibitors and NSAIDs
Tools and Technologies:
Novel and patented delivery systems for novel or existing molecules New formulations of existing antimigraine drugs
MIgrAIne And pAIn: pAIn

Areas of Interest*: Tools and Technologies:
Novel therapeutic agents for neuropathic or inflammatory pain in mechanisms or pathways with human genetic or clinical validation Subtype selective sodium channel blockers Anticonvulsant mechanism of action with evidence for activity in chronic pain Abuse deterrent opioids at or near registration Novel proprietary targets for neuropathic and osteoarthritis pain With selective compounds showing robust preclinical in vivo evidence in appropriate models Agents for treatment of postoperative pain Synergistic combination approaches Therapies providing improved efficacy or safety as add-on or part of novel combination therapy
New models for chronic pain Biomarkers and genetic markers for chronic pain Imaging agents and sensors Alternate formulation (eg, topical) technology
Not Interested in:

Undifferentiated reformulations of marketed products NSAIDs and COX-2 inhibitors iNOS inhibitors Serotonergics Opioids delivered by device FAAH inhibitors or cannabinoid agonists
* Biomarkers: An important aspect for all successful neuroscience licensing submissions is a focus on target engagement, PK / PD, and efficacy and safety biomarkers to be used in conjunction with the program
14
D E C E M B E R
2 0 1 0
NE U R O S C IENC ES
A ND
O pH TH AlMO lO Gy
neuroLogy: ALzHeIMers dIseAse

Broad interest in agents and novel mechanisms with potential disease modifying activity Agents must have demonstrated in vivo activity Targets of interest include: Tau pathophysiology Amyloid secretion, clearance, and / or toxicity Broad interest in agents and novel mechanisms with potential for symptomatic improvement Characteristics at least comparable to existing approved medications With clinical POC, or within pathways with clinical POC May be used as monotherapy or in combination with current therapies
Acetylcholinesterase inhibitors NMDA antagonists AD vaccines Antioxidants Metal chelators Other general neuroprotectants
Collections of CSF from healthy, MCI, and AD subjects Prognostic, diagnostic, and progression biomarkers of disease and disease state with clinical validation Tau and amyloid imaging agents Fluid-based assays for A and tau species (eg, oligomers) Novel animal models for target evaluation Models that develop both plaques and tangles, neuronal loss, cognitive decline correlated with age and pathology Novel genetic / RNA-based approaches to target validation or therapeutics
15
D E C EM B E R
2 0 1 0
N EUROSCIENCES
AND
OpHTH A l M Ol O G y
neuroLogy: pArkInsons dIseAse

Agents and mechanisms for disease modification in genetically or clinically validated pathways Nondopaminergic agents with clinical proof of concept in palliative therapy for Parkinsons disease Nondopaminergic agents that reduce / eliminate L-dopainduced dyskinesias Different formulations of approved products that have demonstrated clinically significant benefits in efficacy, safety / tolerability, and / or dosing vs standard of care
Metal chelators Antioxidants Other general neuroprotectants
Approaches and biomarkers that may identify prodromal stages of disease Animal models of Parkinsons disease progression Pathway biomarkers of neurodegeneration SN-MRI volumetry
opHtHALMoLogy
The following areas of interest apply to compounds that have established POC in clinical Phase II studies and are Phase III-ready and later. Areas of Interest:
Retinal diseases AMD Wet AMD therapies showing less invasive dosing than Lucentis / VEGF-Trap (topical, periocular) and / or additional efficacy Dry AMD therapies to reduce geographic atrophy progression Diabetic retinopathy / diabetic macular edema Mechanisms to reduce progression of NPDR in moderately to severely affected patients Mechanisms to treat patients with existing vision loss with superior efficacy and / or favorable AE profile vs laser and steroids
The trademarks contained herein are the property of their respective owners.
Glaucoma Nonprostanoid MOAs with efficacy and / or tolerability Xalatan Additional properties of interest: trabecular outflow enhancers, nontopical delivery formulations, neuroprotective activity Anterior segment disease Allergic conjunctivitis Bacterial conjunctivitis Dry eye Uveitis
16
D E C E M B E R
2 0 1 0
NE U R O S C IENC ES
A ND
O pH TH AlMO lO Gy
psycHIAtrIc dIseAses
Areas of Interest*:
Novel compounds and chemical leads for: Schizophrenia Monotherapy or add-on therapy for positive, negative, and / or cognitive symptoms Novel mechanisms that modulate clinically validated pathways Mechanisms with clinical POC that lack the adverse event profile of atypical antipsychotics Bipolar, Depression, and Anxiety Agents with clinical POC for monotherapy and / or add-on
Not Interested in:
Monoamine-based atypical antipsychotics SSRI / SNRI
Biological tools and expertise to address nicotinic receptor pharmacology Animal models for psychiatric diseases
sLeep dIsorders (InsoMnIA, excessIve dAytIMe sLeepIness, osA)

Novel therapeutic agents that address unmet needs in sleep difficulties and common co-morbidities Expansion of orexin portfolio (Best in Class and new indications) Novel proprietary targets for Excessive Daytime Sleepiness Synergistic combination approaches Therapies providing improved efficacy or safety as add-on or part of novel combination therapy with Orexin Antagonists
Benzodiazepines Devices for OSA
Biological or physiological markers for insomnia Alternative formulations to facilitate administration to elderly and adolescent patients Diagnostic tool for insomnia
17
D E C EM B E R
2 0 1 0
O NCO lOG y
THE R ApE U T I C S
Oncology Therapeutics
oncoLogy
Areas of Interest:
Late-stage clinical Must demonstrate clinical benefits (improvements in clinical end points) based on results from a Phase IIB program Clinical data in medium-to-large market solid tumor indications or hematological malignancies synergies with current portfolio is a plus Global or regional deals (US, EU, and / or Asia Pacific) Early-stage (up to and including clinical POC) Agents that have synergy with in-house Oncology pipeline therapies in clinical development; agents that have a welldefined responder ID strategy Agents that have efficacy in tumors that are resistant to SOC therapy (preclinical POC data or Phase I data with a clear registration strategy)
Not Interested in (applies to Early and Late Stage):
Preventive care Personalized immunotherapy / autologous therapies Gene therapy Intratumoral delivery (except for RNAi delivery) Radiopharmaceuticals
cApAbILItIes tecHnoLogIes to evALuAte

Areas of Interest:
Biomarkers and diagnostics Diagnostic platforms that are ready for clinical application, including imaging tracers, cell-based, blood, nucleic acid, and IVD capabilities with WW distribution to support in-house Oncology pipeline programs Pharmacodynamic and response biomarkers for PI3K and DNA damage / checkpoint pathways Minimally invasive platforms for measuring tumor biology: circulating tumor cells, circulating nucleic acids, novel imaging tracers (particularly those in the PI3K pathway or those used to assess apoptosis) RNAi Tumor-targeted delivery systems for systemic administration of RNAi Relevant preclinical models of HCC for the evaluation and validation of siRNA targets
Other Robust technology that could predict in vitro therapeutic index of combination therapies Platforms that have high predictive value for clinical efficacy (eg, primary tumors passaged in mice) Genome-wide scanning with the ability to measure copy # variation in tumor samples in a CLIA-certified lab Gene expression from FFPET in a CLIA-certified lab Sequencing in a CLIA-certified lab Software tools to correlate genomic data with clinical outcomes for oncology
18
D E C E M B E R
2 0 1 0
R E SpI R ATO Ry
A ND
I MMU NOlO Gy
Respiratory and Immunology

ArtHrItIs And IMMune-bAsed dIseAses
Disease-modifying antirheumatic drugs (DMARDs) with a strong preference for: Mechanisms targeting clinically proven pathways Mechanisms effective in patients with an inadequate response to anti-TNFa therapies Th17 pathway modulators Cartilage / joint imaging technologies Biomarkers that can be used for patient segmentation Disease-modifying drugs for psoriasis, SLE, or IBD that have achieved POC in Phase II trials Disease-modifying osteoarthritis drugs (DMOADs) with clinical POC and a clearly defined path to registration
Drugs whose primary clinical indication is the prevention of graft rejection
19
D E C EM B E R
2 0 1 0
RESpIRATOR y
AND
IM M U N Ol O Gy
AstHMA / copd / rHInItIs

Compounds / biologics for asthma Anti-inflammatory agents with novel mechanisms Anti-inflammatory agents, additive or differentiated from a glucocorticoid Anti-inflammatory agents that are effective in glucocorticoid-resistant asthma Selective glucocorticoid receptor modulators Novel and / or differentiated bronchodilator mechanisms Inhaled compounds including combination therapies Compounds / biologics for COPD with clinical POC or compelling biological rationale Oral or inhaled compounds including combination therapies Disease-modifying compounds for rhinitis, atopic dermatitis, and allergy with clinical POC Technologies Biomarkers Predictive animal models of asthma pathophysiology Human lung cell / tissue-based systems for investigating new therapeutic mechanisms Translational medicine platforms Inhaled technologies / formulations that provide improved drug delivery / compliance / patient acceptance
Acute lung injury Antioxidants (ie, direct scavengers) Adenosine antagonists (A1, A2, and A3) Antihistamine antagonists (H1, H2) IL5 antagonists Leukotriene receptor antagonists VLA4 antagonists
20
D E C E M B E R
2 0 1 0
W O M E NS
H EA lTH
A ND
END O C R I NOlO Gy
Womens Health and Endocrinology

contrAceptIon
Novel targets and molecular pathways for contraception Compounds and biologicals for contraceptive targets Basic research collaborations towards validation of novel targets for contraception Male contraception
Emergency contraception
Biomarkers Methods, translational biomarkers for reproductive biology Delivery / Formulation Novel delivery / formulation technologies
21
D E C EM B E R
2 0 1 0
WOMEN S
H EAlTH
AND
ENDO C R I N Ol O G y
fertILIty
Compounds / biologics for female infertility Novel mechanism of action related to female fertility Targets for infertility treatment Basic research collaborations towards validation of novel targets
Progestagens for luteal support Obstetrics
Discovery Cell-based screening assays for testing compounds Technologies for identifying novel targets for infertility treatment Biomarkers Biomarkers and diagnostics for endometrial quality / implantation and efficacy Biomarkers for oocyte / embryo quality Delivery / Formulation Novel delivery / formulation technologies for biologicals for fertility
MenopAuse
Areas of Interest:
Compounds / biologics for menopausal complaints Basic research collaborations related to the discovery and / or validation of novel targets
Discovery Novel targets for menopausal complaints Technologies for identifying novel targets for menopause Preclinical models of menopausal complaints Biomarkers (clinical and preclinical) Biomarkers for treatment of menopausal complaints
22
D E C E M B E R
2 0 1 0
W O M E NS
H EA lTH
A ND
END O C R I NOlO Gy
endoMetrIosIs
Compounds and biologicals for endometriosis Novel targets / pathways for endometriosis Anti-inflammatory approaches Pain prevention methods (endometriosis-specific pain) Basic research collaborations towards validation of novel targets
Contraceptives for use in endometriosis treatment
Discovery Diagnostics / imaging techniques Translational animal models Methods to score efficacy of endometriosis treatments Technologies for identifying novel targets for endometriosis Preclinical models of endometriosis Biomarkers (clinical and preclinical) Biomarkers for endometriosis
bone
Osteoanabolic agents Novel mechanisms with known molecular target Biomarkers Surrogate biomarkers of bone strength and / or fracture risk More sensitive and faster biomarkers of bone anabolism Selective markers for cortical and trabecular bone anabolism Markers for specific bone loss / fracture risk in: Postmenopausal and male osteoporosis Glucocorticoid osteoporosis Cancer-related bone loss Novel bone-imaging technologies and measures of bone quality Osteoporosis diagnostics Self-assessment tools Inexpensive BMD / BMx and fracture risk measures
Growth hormone or secretagogues ER alpha agents Classic antiresorptive agents, including bisphosphonates with improved formulations that allow less frequent dosing or better tolerability
23
D E C EM B E R
2 0 1 0
WOMEN S
H EAlTH
AND
ENDO C R I N Ol O G y
uroLogy
Novel therapies for OAB (Phase I or greater) Novel therapies for stress urinary incontinence (Phase I or greater) Novel therapies for BPH (Phase I or greater) Biomarkers Surrogate biomarkers of bladder dysfunction Imaging approaches for indices of bladder function, including control of bladder function Diagnostics to improve specificity of diagnosing OAB from stress incontinence Diagnostics to predict response or nonresponse to therapy including anticholinergics or other mechanisms of action
Anticholinergics for OAB (unless Phase III or later) 5a reductase inhibitors for BPH Alpha-1 adrenergic blockers for BPH
sArcopenIA
Mechanisms that preserve / restore fibers (both biologics and small molecule) Myoanabolic agents and targets Anticatabolic agents and targets Translational models Mechanisms that improve fiber function (both biologics and small molecule) Neuromuscular junction / alpha motor unit maintenance Fiber recruitment Fiber type switching Fiber metabolism Sarcomere dysfunction Biomarkers and diagnostics Biochemical markers of muscle functional state (remodeling, metabolism) Imaging markers of muscle function Physical tests
Growth hormone (GH), growth hormone-releasing hormone (GHRH), or derivatives by any route Growth hormone secretagogues
otHer dIseAses
Areas of Interest:
Compounds, medications, and / or treatments with new mode of actions in the following areas Uterine fibroids Dysmenorrhea Sexually transmitted diseases Female sexual dysfunction
24
D E C E M B E R
2 0 1 0
B I OlO G I C S
Biologics
bIoLogIcs
Biosimilars Novel biologics and biobetters that fit franchise strategies Novel devices for SQ and IV delivery
Transgenic animal-based or plant-based production systems for therapeutics Inhaled delivery of biologics
Technologies of Interest:
Fc engineering to enhance / improve effector functions, half-life Targeted delivery technologies that: Address / overcome the blood brain barrier Glycan mediated targeting Bispecific platforms with promising stability and manufacturing yield Technologies that enhance expression, production, formulation, stability, and bioavailability (via SQ admin) of proteins Platforms for the identification, generation, and modification of monoclonal antibodies (mAbs, Fabs, scFvs) and engineered proteins displaying pharmaceutical properties High throughput screening Including function-based screens De-immunization
25
D E C EM B E R
2 0 1 0
vA C C I N E S
Vaccines
vAccInes
Areas of Interest: Tools and Technologies:
Viral, bacterial, fungal vaccine candidates in areas of high medical need / high incidence Preclinical efficacy or clinical POC achieved, an advantage but not required HIV: Novel immunogens that elicit broadly crossneutralizing immunity antibodies Influenza: Universal flu vaccines: Preclinical data demonstrating broadly cross-reactive HAI and / or neutralizing antibodies (ie, not just cellular immunity) and protection from challenge (survival and weight loss) comparable to seasonally matched control vaccines Seasonal influenza vaccines that have clinical data demonstrating differentiation from marketed products, eg, higher HAI and / or neutralizing antibodies in elderly subjects Improvements on existing in-house vaccines, which would allow for reduced dosing or increased cross-strain protection Novel adjuvants and immunomodulators Highly desirable if preclinical efficacy or clinical POC achieved, but not necessarily required Preclinical toxicology data demonstrating acceptable safety profile
Novel technologies for: Antigen selection, discovery, and identification Viral vector approaches Vaccine administration, eg, dermal or mucosal delivery of vaccines Multiplexed clinical assay platforms Production of virus-like particles Studying human cellular and B cell responses to vaccination, including novel human tissue culture systems and humanized mouse systems Enhance thermostability of vaccines during transport and storage Novel cell lines for vaccine or recombinant protein production, preferably with Phase I safety data
Not Interested in:
Biodefense targets Products containing thimerosal or unmodified animal / human components Seasonal vaccines (eg, influenza) that are not clinically differentiated from marketed products DNA-based vaccines for infectious diseases Viral vectors based on pox viruses, retroviruses, and adeno-associated viruses
26
D E C E M B E R
2 0 1 0
R ES EA R C H
TEC H NOl O G I ES
Research Technologies
rnA tHerApeutIcs
Areas of Interest:
siRNA delivery platforms for systemic and / or local administration Ability to demonstrate dose-dependent, RNAi-mediated gene silencing in vivo with at least a 10-fold margin for severe toxicities Chemical and / or biological components suitable for enhancing cellular uptake, intracellular trafficking, endosomal escape, and cytosolic release of oligonucleotides Chemical and / or biological components capable of conferring improved biocompatibility of RNA nanoparticles / formulations Targeting ligands (antibodies, peptides, aptamers, or small molecules) suitable for direct siRNA conjugation or for nanoparticle, polymer, or liposome delivery Assays Novel particle size characterization methods Novel colloid surface characterization methods Biochemical assays for Ago / RISC binding and catalytic activity siRNA sequence, structure, and modification Novel chemistries for: Improving resistance to enzymatic and chemical degradation Reducing immunostimulation Enhancing Ago2 / RISC incorporation and potency Improving target specificity Predictive bioinformatic and molecular models
miRNA Novel chemistries to create miRNA mimics and / or antagonists Assays for pharmacodynamic evaluation of miRNA activity Potential therapeutic agents that: Reduce miRNA levels in animals and generate the expected phenotypic effects Mimic natural miRNA, reduce mRNA levels, and have the expected phenotypic effects RNA manufacturing Advancements in large-scale production of modified siRNA Improved processes for increased quality, efficiency, and reduced COG Novel chemistries Universal linker-based solid support for production of siRNAs Robust LC-MS method for determination of impurity profile of phosphoramidite raw materials and oligonucleotides (siRNAs) Alternative methods to produce siRNA clinical supplies AAV production High-titer, high-volume AAV production for non-clinical applications and POC
Not Interested in:
Plasmid DNA-based methods for RNA therapies Viral delivery methods for RNA therapies Aptamers as therapeutics
27
D E C EM B E R
2 0 1 0
RESEARCH
TEC H N O l O G I E S
drug deLIvery And forMuLAtIon

Areas of Interest:
Oral delivery technologies: Technologies for delivery of water-insoluble compounds (especially mitigation of food effect) Oral-controlled release technologies to modify pharmacokinetics (eg, increase Cmax, AUC, and / or T1/2 , reduce peak-to-trough ratio): For poorly soluble compounds (<0.1 mg / mL) For compounds with narrow absorption windows (eg, those with poor colonic absorption) Ingredients or formulations that can enhance permeability Orally disintegrating tablet (ODT) technology or film technology with robust in vivo performance and simple packaging Sublingual delivery for fast onset Technologies that protect actives from the GI environment (eg, gastric acid or GI metabolism) Novel oral protein / peptide delivery systems (eg, insulin) Inhalation / nasal delivery: Delivery systems for small and large molecules Novel in situ modeling (eg, lung solubility or IVIVC) Injectable delivery, alternative routes of administration: Injection devices (eg, novel and easy-to-use selfinjection systems, improved liquid / dry reconstitution technologies) Infusion systems (IV and subcutaneous delivery that facilitate hospital and home infusion therapies) Novel skin-based delivery technologies for high concentration antibody formulations and large volumes of liquid (>2 mL) Technologies for delivery of water-insoluble compounds (eg, IV-administered nanosuspensions or dispersed systems for small molecules and peptides) Systems (including implants) for sustained release of small and large molecules from one week to several months, up to years (long-acting implants) Vaginal ring and intrauterine delivery
Back-of-the-eye delivery systems (eg, invasive and noninvasive, clinically proven technologies for retinal delivery of small molecules, siRNAa and trophic factors) Novel passive and active transdermal and topical technologies for small molecule and peptideb delivery Intelligent delivery systems capable of modulated delivery (eg, signal or drug concentration); personalized / feedback control Technology with potential to improve compliance with any dosage form especially for pediatric and geriatric populations Delivery formulations or targeting ligands that provide selectivity and activity through enhanced cell association and uptake in target tissues
See RNA Therapeutics section for complete listing of interests related to delivery of nucleic acids. See Peptide Therapeutics section for complete listing of interests in peptide delivery.
28
D E C E M B E R
2 0 1 0
ENA B lI NG
TEC H NOlO G I ES
Enabling Technologies
trAnsLAtIonAL ModeLs / In vIvo pHArMAcoLogy
Areas of Interest:
In vivo platforms that replicate human metabolism and disease state Technologies to assess gene function in tissue-specific manner for MOA and target tissue specificity In vivo models with improved assessment of human-specific ADME and safety / toxicity In vitro platforms that robustly reproduce clinical indications, ADME, and clinical safety / toxicity Label free assay / non-invasive in vivo technologies capable of translating from basic to clinical for MOA, drug distribution, and safety / toxicity
bIoMArkers
Areas of Interest:
Quick-turnaround mid-density expression, genotyping, protein expression platforms Technologies that can perform multiplexed biomarker analysis with wide dynamic range RNA, proteins, peptides, and / or small molecules Animals and / or clinic More streamlined with fewer repeats due to dilutions for individual analytes Identify vendors / academics that have identified and / or discovered / validated / qualified biomarkers Translation to humans (cell lines human cells animals humans) Target engagement, pharmacologic activity, efficacy, and toxicity Sources of samples or model systems for biomarker discovery and development
29
D E C EM B E R
2 0 1 0
ENAB lING
TEC H N Ol O G I E S
LeAd IdentIfIcAtIon And screenIng AssAys

Areas of Interest:
Improved miniaturized high throughput assays for MoA and toxicity assays Toxicity Assessment with limited amounts of compounds Continuous kinetic cell-based assays of second messenger kinetics (Ca++, cAMP, phosphorylation, Ion Channels, etc) for determination of On rate, Off rate, desensitization in cellular contest Measurements of the GPCR-mediated physiological responses, including heterodimer formation Cellular protein-protein interactions Technologies for automated siRNA and cDNA screening Physiological cellular models and translational ex vivo cellular models In vitro / ex vivo / in vivo predictive models Improved technologies for primary cell immortalization of disease tissues Metabolically competent hepatocyte-like cellular systems Improvement on BACMAM vectors for cell transfection Disease predictive physiological cellular models High throughput imaging and flow cytometry platforms Advanced cellular image analysis software Imaging-based tools to measure morphological / biomechanical changes in cells High throughput flow-based imaging for screening primary stem cells 3D-imaging tools and analysis software Novel fluorophores for measurements of the cellular changes, including structural proteins
cHeMIcAL syntHesIs And purIfIcAtIon

Areas of Interest (Chemical Synthesis): Areas of Interest (Purification):
Improved reactions Asymmetric cyclopropanation Selective functionalization of heterocyclic compounds Nitroreductases as a platform for accessing chiral aliphatic amines, and anilines Greener oxidations Method to determine the cost of separations for scale up reactions Enzyme immobilization t-Bu cross-coupling Automation tools for DOE experiments Analysis and purification of lipids 14C labeled carbonylation N=O chemistry Preparation of alkyl fluorides C-H oxidations Reactions to introduce fluorine and CF3
Scalable membrane separations One shot separations system
30
D E C E M B E R
2 0 1 0
ENA B lI NG
TEC H NOlO G I ES
ModeLIng tooLs
Areas of Interest:
ADME models and databases Large, diverse datasets for less common metabolic pathways, such as aldehyde oxidase, sulfotransferases, BCRP, and other transporters, etc Models for observable phenomena that are composites of multiple processes, eg, bioavailability, volume of distribution, clearance Ligand design Fragment-based de novo design software Assessment of relative synthetic tractability with performance appropriate for prioritizing thousands to millions of novel structures Protein and protein-ligand modeling Reliable screening of multiple mutations including multiple templates Antibody structure prediction and protein loop prediction Flexible backbone design and simultaneous de novo modeling of multiple loops Ab-initio prediction of protein structures, including cases where predicted domain is part of a multi-domain protein or complex 3D docking software for pose prediction that incorporates binding site flexibility and alternate protonation states Molecular mechanics and dynamics Setup and analysis software for MD calculations Molecular mechanics force-fields that can reliably model geometries and energies of small molecules and proteins including solvent effects Virtual screening for lead finding and lead optimization Ligand or protein-based methods to find actives more efficiently with demonstrated performance on experimental datasets for multiple targets Ligand or protein-based methods to find actives representing greater diversity of chemical classes with demonstrated performance on experimental datasets for multiple targets Improved scoring for compound ranking that include explicit waters or configurational entropy with demonstrated ranking performance on experimental datasets for multiple targets in 3D docking experiments (eg, methods)
AutoMAted WorkfLoWs
Areas of Interest:
Microfluidics Coupling microfluidics to conventional automation and analytical tools to maximize productivity, eg, Empyrean microfluidic UV / Vis plate reader Miniaturization of screening tools compatible with organic solvents capabilities for analytical measurements, reactions, formulations Nanoscale sample transfer automation 1100 nL range with improved precision / accuracy and speed, solvent compatibility Acoustic, inkjet, piezo-based technologies MicroArray type methodologies applied to chemical / analytical questions Consolidation of sample prep unit operations with analytical autosamplers Sample filtration, dilution, quenching, pretreatment, etc, for compounds, tablets, etc Coupling conventional HTS liquid handling approaches with techniques beyond plate readers Automation of routine sample / buffer preparation Quick-turnaround mid-density expression, genotyping, protein expression platforms
31
D E C EM B E R
2 0 1 0
ENAB lING
InforMAtIon tecHnoLogy / softWAre

Areas of Interest:
Knowledge management and data-mining tools Finding and accessing existing data Ability to integrate external and internal datasets Technology to improve information connectivity and sharing within MRL as well as with external partners Information and document tagging technologies for smart retrieval of information and documents for export and data / text mining Technology to support the reusability of information, eg, through collaborative / structured authoring Knowledge capture technology to capture tacit knowledge as well as when knowledge is generated through collaborative research Collaboration tools Collaborative contribution / decision-making tools, eg, such as predictive market technology Workflow management Ability to track work requests between groups and perform resource management / prioritization In vivo information technology platforms Global in vivo database and analytical platform for preclinical data and ability to compare associated clinical data Animal facility management tools Modeling, and predictive analysis capabilities that: Allow better prediction of in vivo (human) drug performance based on in vitro testing Sharing of macromolecular structure models Efficient, easy-to-use software for visualizing, manipulating, and processing large amount of data Multidimensional data analysis and reporting tools
AnALytIcAL tecHnoLogy
Areas of Interest:
Improved efficiency of analytical workflows Fast and high throughput analysis tools More efficient analytical method development Novel PAT tools Automation of analysis Methods to analyze large molecules (siRNAs, peptides, polymers), biologics, and vaccines Improved platform analytical tools (HPLC, MS, etc) that require smaller samples, including microfluidic devices to run complex analytical assays
32
D E C E M B E R
2 0 1 0
ENA B lI NG
TEC H NOlO G I ES
Mapping of Franchise AOIs to Corresponding Technology AOIs for Potential Platform Extensions:
Athero and Cardio Target Identification / Validation Novel lipid / metabolic and / or other emerging targets with high confidence for reducing CV risk Novel targets for specialty hypertension Translational Models / In Vivo Pharmacology Animal models of hypertension Predictive animal models of asthma pathophysiology Models for endometriosis Animal or cellular viral latency models Animal or cellular viral latency models Robust cell culture systems for HCV replication Models that develop both plaques and tangles and that show neuronal loss New models for chronic pain Parkinsons disease progression models Models for psychiatric diseases Biological tools to address nicotinic receptor pharmacology Robust In Vitro Platforms That Translate to Animal and Human Studies In vitro tissue models for HCV In vitro therapeutic index of combination therapies Identification, generation, and modification of monoclonal antibodies and engineered proteins displaying pharmaceutical properties Models of HCC for the evaluation and validation of siRNA targets Antigen selection, discovery, and Identification Respiratory and Immunology Human lung cell/ tissue-based systems for investigating new therapeutic mechanisms Womens Health Targets for menopausal complaints Diabetes and Obesity Platform technologies for the identification and validation of novel targets Infectious Diseases Neuro and Ophthalmology Novel genetic / RNA-based approaches to target validation or therapeutics Oncology Biologics Vaccines
Biomarkers
Methods, biomarkers, or platforms to assess antiatherogenic properties of HDL or other lipoproteins Biomarkers of patient subtypes Technologies for measuring vascular dynamics and intravascular pressure beyond tonometry Markers that link HTN to other metabolic syndrome phenotypes and /or atherosclerosis Markers for renal sequelae of HTN Platform technologies that enable personalized medicine for HTN
Biomarkers that can be used for patient segmentation Translational medicine platforms
Biomarkers for reproductive biology, oocyte / embryo quality, endometrial quality / implantation, menopausal complaints and endometriosis Surrogate biomarkers of bone strength and / or fracture risk Selective markers for cortical and trabecular bone anabolism Markers for specific bone loss / fracture risk Surrogate biomarkers of bladder dysfunction Biochemical markers of muscle functional state associated with sarcopenia
Pharmacogenetics / -genomics, proteomics, or other for prediction of diabetes, obesity, drug response, and sub-phenotyping of disease
Prognostic HIV and HCV markers Molecular biomarkers of susceptibility
Markers for chronic pain Parkinsons disease markers that may identify prodromal stages Neurodegeneration pathway markers
Markers for PI3K and DNA damage / checkpoint pathways Minimally invasive platforms for measuring circulating tumor cells, circulating nucleic acids, novel imaging tracers.
Near Real-time Assays to Screen Patients Faster for Clinical Trials
Acute methods to assess cholesterol transport in humans (especially reverse cholesterol transport), including imaging and kinetic models
Clinical methods for early prediction of long-term weight loss
The complete therapeutic area technology needs can be found in the associated therapeutic area section of the book.
33
D E C EM B E R
2 0 1 0
ENAB lING
Mapping of Franchise AOIs to Corresponding Technology AOIs for Potential Platform Extensions:
Athero and Cardio Diagnostics / Imaging Techniques and Genotyping / Phenotyping Respiratory and Immunology Womens Health Methods to detect endometriosis Imaging approaches for indices of bladder function Diagnostics to improve specificity of diagnosing OAB from stress incontinence Diagnostics to predict response to therapy including anticholinergics or other mechanisms of action associated with urology related disorders Production, Purification & Analysis Fc engineering to enhance / improve effector functions, half-life Bispecific platforms with promising stability and manufacturing yield Drug Delivery and Formulation Inhaled technologies / formulations Contraceptive technologies Novel delivery / formulation technologies for biologicals for fertility, contraception Alternate delivery of peptides Novel delivery devices for sc insulin PK enhancers Novel delivery systems for novel or existing migraine treatments New formulations of existing antimigraine drugs Tumor-targeted delivery systems for systemic administration of RNAi Methods to address blood brain barrier Glycan mediated targeting Dermal or mucosal delivery Diabetes and Obesity Imaging agents for monitoring pancreatic betacell mass Infectious Diseases Genotyping and phenotyping technologies for HCV polymerase and HCV protease Rapid point-ofcare, pathogenspecific and host-response diagnostic tests Neuro and Ophthalmology CSF collections from healthy, MCI and AD subjects Tau and amyloid imaging agents Fluid-based assays for A, ADDLs, and tau SN-MRI volumetry Oncology Imaging tracers, cell-based, blood, nucleic acid, and IVD diagnostics Genome-wide scanning with the ability to measure copy number variation in tumor samples Gene expression from FFPET Biologics Vaccines
Information Technology / Knowledge Management
The complete therapeutic area technology needs can be found in the associated therapeutic area section of the book.
34
D E C E M B E R
2 0 1 0
A R EA S
O f
I NTER ES T
notes
35
D E C EM B E R
2 0 1 0
AREAS
Of
I N T E R E S T
notes
36
Merck is passionate about our commitment to partnering. Lets explore the possibilities of combining our strengths to deliver novel medical breakthroughs that save and improve lives.
David Nicholson, PhD, Senior Vice President and Head Worldwide Licensing and Knowledge Management
CENTRAL SCIENTIFIC LICENSING CONTACT
KOREA
INDIA, PHILIPPINES, vIETNAM, AND INDONESIA
Greg Wiederrecht, PhD, CLP

Vice President and Head, External Scientific Affairs Worldwide Licensing Merck Research Laboratories PO Box 2000 Rahway, NJ, USA 07065-0900 Email: greg.wiederrecht@merck.com Phone: +1 732 594 6576
Kuchan Kimm, MD, PhD

Science Ambassador, External Scientific Affairs Worldwide Licensing MSD 168 Gongduk-dong, Mapo-gu 9F Mirae Asset Life Insurance Building Seoul 121-705, Korea Email: kuchan.kimm@merck.com Phone: +82 2 6363 0012 (Direct) Phone: +82 10 4100 3216 (Mobile)
Swami Subramaniam, MD, PhD

Director, External Scientific Affairs Worldwide Licensing MSD 8th Floor, Platina, Plot No C-95 G Block, Bandra Kurla Complex Bandra (East), Mumbai 400098, India Email: swami.subramaniam@merck.com Phone: +91 98455 44147
UNITED KINGDOM, ITALY, AND SWITZERLAND
NEW ENGLAND AND LATIN AMERICA
JAPAN
Margaret Beer, MSc, PhD

Senior Director, External Scientific Affairs Worldwide Licensing MSD Hertford Road Hoddesdon, Herts EN11 9BU, United Kingdom Email: margaret.beer@merck.com Phone: +44 1992 452839
Reid J. Leonard, PhD

Executive Director, External Scientific Affairs Worldwide Licensing Merck Research Laboratories 33 Avenue Louis Pasteur, BMB 2422A Boston, MA, USA 02115 Email: rj.leonard@merck.com Phone: +1 617 992 2321
Jun Suzuki, DvM, PhD

External Scientific Affairs Worldwide Licensing MSD K.K. Kitanomaru Square 1-13-12, Kudan-kita Chiyoda-ku, Tokyo 102-8667 Japan , Email: jun.suzuki@merck.com Phone: +81 3 6272 1836
CENTRAL CORPORATE LICENSING CONTACT
SCANDINAvIA, BALTIC STATES, CENTRAL EUROPE, AUSTRIA, THE BALKANS, GREECE, AND TURKEY
BENELUX, RUSSIA, ISRAEL, AND SOUTH AFRICA
Pamela Demain, MBA, CLP

Executive Director, Corporate Licensing Merck PO Box 100 Whitehouse Station, NJ, USA 08889-0100 Email: pamela.demain@merck.com Phone: +1 908 423 6940
Erik Lund, PhD, CLP

Director, External Scientific Affairs Worldwide Licensing MSD Rotebergsvgen 3, Box 7125 192 07 Sollentuna, Sweden Email: erik.lund@merck.com Phone: +1 732 594 2904
Jeroen Tonnaer, PhD

Senior Director, External Scientific Affairs Worldwide Licensing MSD Molenstraat 110, 5342 CC Oss PO Box 20, 5340 BH Oss The Netherlands Email: jeroen.tonnaer@merck.com Phone: +31 412 668867
FRANCE AND GERMANY
SOUTHEASTERN UNITED STATES
NORTHWEST UNITED STATES
Manfred Horst, MD, PhD, MBA

Director, External Scientific Affairs Worldwide Licensing MSD 3 Avenue Hoche 75114 Paris, France Email: manfred.horst@merck.com Phone: +33 1 4754 8858
Sanjeev Munshi, PhD, MBA

Director, External Scientific Affairs Worldwide Licensing Merck Research Laboratories 5325 Old Oxford Road Durham, NC, USA 27712 Email: sanjeev.munshi@merck.com Phone: +1 267 305 1793
Yael Weiss, MD, PhD

Director, External Scientific Affairs Worldwide Licensing Merck Research Laboratories 1700 Owens Street, Suite 400 San Francisco, CA, USA 94158 Email: yael.weiss@merck.com Phone: +1 415 627 8781
CHINA, HONG KONG, AND TAIWAN
UNITED KINGDOM, IRELAND, PORTUGAL, AND SPAIN
CANADA AND PORTIONS OF UPPER MIDWEST UNITED STATES
Jing-Shan (Jennifer) Hu, PhD

Director, External Scientific Affairs Worldwide Licensing MSD 20F Park Place, 1601 Nanjing Road (West) Shanghai 200040, China Email: jing.shan.hu@merck.com Phone: +86 21 2211 8535
Robert Pinnock, BSc, PhD

Director, External Scientific Affairs Worldwide Licensing MSD Hertford Road Hoddesdon, Herts EN11 9BU, United Kingdom Email: rob.pinnock@merck.com Phone: +44 1992 452850
Steven Xanthoudakis, PhD

Director, External Scientific Affairs Worldwide Licensing Merck Research Laboratories 9-2-446A, Research Building 9 16711 Trans Canada Highway Kirkland, Quebec H9H 3L1, Canada Email: steven.xanthoudakis@merck.com Phone: +1 514 428 3461
JAPAN
MID-ATLANTIC, SOUTHEAST, AND MIDWEST UNITED STATES
Koichi Kato, PhD

Senior Director, External Scientific Affairs Worldwide Licensing MSD K.K. Kitanomaru Square 1-13-12, Kudan-kita Chiyoda-ku, Tokyo 102-8667 Japan , Email: koichi.kato2@merck.com Phone: +81 3 6272 2209
Susan Rohrer, PhD

Senior Director, External Scientific Affairs Worldwide Licensing Merck Research Laboratories PO Box 2000 Rahway, NJ, USA 07065 Email: susan.rohrer@merck.com Phone: +1 732 594 7499
Visit our Web site merck.com/licensing

Merck is known as MSD outside the United States and Canada.
AUSTRALIA, NEW ZEALAND, MALAYSIA, AND SINGAPORE
SOUTHWEST UNITED STATES
Phil Kearney, PhD, MBA

Director, External Scientific Affairs Worldwide Licensing MSD 5468 Ferndell Street South Granville, New South Wales Australia, 2142 Email: phil.kearney@merck.com Phone: +61 2 9795 9500
James Schaeffer, PhD

Executive Director, External Scientific Affairs Worldwide Licensing Merck Research Laboratories 7825 Fay Avenue, Suite 320 La Jolla, CA, USA 92037 Email: jim.schaeffer@merck.com Phone: +1 858 454 6502 ext. 102
Copyright 20092010 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved. LIC-2010-W-85943-AH

Merck Interest Areas

Transféré par

Informations du document

Description originale:

Copyright

Formats disponibles

Partager ce document

Partager ou intégrer le document

Options de partage

Avez-vous trouvé ce document utile ?

Ce contenu est-il inapproprié ?

Droits d'auteur :

Formats disponibles

Merck Interest Areas

Transféré par

Droits d'auteur :

Formats disponibles

C O M B I N I N G S H A R I N G

Merck is known as MSD outside the United States and Canada.

David Nicholson, PhD

Deal MakingA Creative and Flexible Process

Step 1 Connecting With You

Step 2 Understanding Your Science

Step 3 Doing the Deal

Step 4 Working Together

Therapeutic Areas and Research Technologies

Diabetes and Obesity

Neurosciences and Ophthalmology

Respiratory and Immunology

Womens Health and Endocrinology

We have aligned our areas of interest with our

Additionally, we will continue to pursue

We will also pursue niche acquisitions and

CARDIO vASCU lAR

Atherosclerosis and Cardiovascular Diseases

specIALty HypertensIon* / cArdIovAscuLAr

ACE inhibitors, ARBs, CCBs, beta-blockers, adrenergic agents Nutraceuticals

CARDIO vASCU lAR

tHroMbosIs And otHer AreAs (outsIde LIpIds And HypertensIon)

Not Interested in:

Antiarrhythmic agents for atrial fibrillation

Diabetes and Obesity

dIAbetes And obesIty

Late-stage opportunities (Phase III-ready and later):

Late-stage opportunities (Phase III-ready and later):

Not Interested in:

Agents administered parenterally, including antibodies

Not Interested in:

AntIvIrALs otHer Interests

Not Interested in:

Agents administered parenterally

AntIvIrAL And AntI-InfectIve tecHnoLogIes

Antifungal and Antibacterial:

Neurosciences and Ophthalmology

Triptans COX-2 inhibitors and NSAIDs

Tools and Technologies:

MIgrAIne And pAIn: pAIn

Not Interested in:

neuroLogy: ALzHeIMers dIseAse

Tools and Technologies:

neuroLogy: pArkInsons dIseAse

Metal chelators Antioxidants Other general neuroprotectants

Tools and Technologies:

Not Interested in:

Monoamine-based atypical antipsychotics SSRI / SNRI

Tools and Technologies:

sLeep dIsorders (InsoMnIA, excessIve dAytIMe sLeepIness, osA)

Benzodiazepines Devices for OSA

Tools and Technologies:

Not Interested in (applies to Early and Late Stage):

cApAbILItIes tecHnoLogIes to evALuAte

Respiratory and Immunology

Drugs whose primary clinical indication is the prevention of graft rejection

AstHMA / copd / rHInItIs

Womens Health and Endocrinology

Progestagens for luteal support Obstetrics

Contraceptives for use in endometriosis treatment

Not Interested in:

Not Interested in:

drug deLIvery And forMuLAtIon